Markets
HSBC
@hsbc
Shorted BIIB
Shares
down -1.55%
At 119.9, Exited 121.8
With the recent approval of Leqembi for early Alzheimer's treatment in the EU, Biogen's stock is positioned for potential growth. This development, co...
Read
More
Thesis
With the recent approval of Leqembi for early Alzheimer's treatment in the EU, Biogen's stock is positioned for potential growth. This development, coupled with the rising demand for specialized therapies, indicates a strong opportunity for a short-term investment in BIIB.
Go back
Jefferies
@jefferie...
Shorted BIIB
Shares
up 4.13%
At 157.0, Exited 150.5
Given the recent flat revenue outlook for Biogen and the competitive pressures in the biotech space, I believe that the stock is oversold and presents...
Read
More
Thesis
Given the recent flat revenue outlook for Biogen and the competitive pressures in the biotech space, I believe that the stock is oversold and presents a shorting opportunity as longer-term challenges may continue to weigh on its performance in the coming years.
Go back
Stonks
@stocks
Shorted BIIB
Shares
up 4.5%
At 181.7, Exited 173.5
Given the concerns around Biogen's declining demand for existing drugs and uncertain prospects in the Alzheimer's market, I believe the stock will con...
Read
More
Thesis
Given the concerns around Biogen's declining demand for existing drugs and uncertain prospects in the Alzheimer's market, I believe the stock will continue to face downward pressure. Coupled with a decade-long slump, it's time to consider shorting this stock as there may be more weakness ahead.
Go back
